Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Botswana | 117 | 2024 | 1058 | 4.680 |
Why?
|
HIV Infections | 135 | 2024 | 17569 | 3.770 |
Why?
|
HIV-1 | 73 | 2024 | 6961 | 3.740 |
Why?
|
Anti-HIV Agents | 49 | 2024 | 4573 | 2.240 |
Why?
|
Viral Load | 41 | 2024 | 3396 | 2.000 |
Why?
|
Drug Resistance, Viral | 20 | 2024 | 869 | 2.000 |
Why?
|
HIV Seropositivity | 16 | 2024 | 966 | 1.640 |
Why?
|
RNA, Viral | 23 | 2021 | 2872 | 1.610 |
Why?
|
Hepatitis B | 12 | 2024 | 711 | 1.230 |
Why?
|
Anti-Retroviral Agents | 18 | 2023 | 1789 | 1.190 |
Why?
|
Infectious Disease Transmission, Vertical | 21 | 2024 | 1354 | 1.120 |
Why?
|
Hepatitis B virus | 12 | 2024 | 533 | 1.080 |
Why?
|
Alphapapillomavirus | 5 | 2022 | 219 | 1.030 |
Why?
|
Pregnancy Complications, Infectious | 22 | 2024 | 2185 | 0.960 |
Why?
|
Wolves | 1 | 2023 | 10 | 0.860 |
Why?
|
Reverse Transcriptase Inhibitors | 6 | 2022 | 620 | 0.840 |
Why?
|
Phylogeny | 22 | 2024 | 2843 | 0.830 |
Why?
|
Papillomavirus Infections | 8 | 2024 | 1640 | 0.810 |
Why?
|
Dog Diseases | 1 | 2023 | 143 | 0.800 |
Why?
|
Genotype | 34 | 2024 | 13045 | 0.760 |
Why?
|
Antiretroviral Therapy, Highly Active | 18 | 2024 | 1903 | 0.750 |
Why?
|
Heterocyclic Compounds, 3-Ring | 7 | 2024 | 296 | 0.740 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2016 | 620 | 0.730 |
Why?
|
HIV Reverse Transcriptase | 2 | 2019 | 214 | 0.680 |
Why?
|
HIV Antigens | 2 | 2018 | 328 | 0.650 |
Why?
|
Hepatitis B Surface Antigens | 7 | 2024 | 294 | 0.610 |
Why?
|
CD4 Lymphocyte Count | 19 | 2023 | 2596 | 0.610 |
Why?
|
Oxazines | 8 | 2024 | 358 | 0.610 |
Why?
|
Serologic Tests | 2 | 2018 | 382 | 0.560 |
Why?
|
Meningitis, Cryptococcal | 3 | 2022 | 67 | 0.550 |
Why?
|
Hepatitis Delta Virus | 3 | 2024 | 24 | 0.530 |
Why?
|
Caliciviridae Infections | 3 | 2021 | 29 | 0.520 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 5 | 2020 | 213 | 0.510 |
Why?
|
Antibody Affinity | 1 | 2016 | 252 | 0.500 |
Why?
|
Zidovudine | 9 | 2024 | 625 | 0.500 |
Why?
|
Pyridones | 8 | 2024 | 819 | 0.480 |
Why?
|
Hepatitis D | 2 | 2024 | 23 | 0.470 |
Why?
|
Mutation | 24 | 2024 | 30238 | 0.470 |
Why?
|
Uterine Cervical Dysplasia | 4 | 2024 | 392 | 0.460 |
Why?
|
Lamivudine | 5 | 2024 | 367 | 0.440 |
Why?
|
HIV | 12 | 2023 | 1597 | 0.430 |
Why?
|
HIV Antibodies | 9 | 2023 | 1341 | 0.430 |
Why?
|
Uterine Cervical Neoplasms | 5 | 2024 | 2043 | 0.420 |
Why?
|
DNA, Viral | 13 | 2023 | 2204 | 0.420 |
Why?
|
Immunoassay | 1 | 2016 | 746 | 0.410 |
Why?
|
Viremia | 5 | 2024 | 726 | 0.410 |
Why?
|
Breast Feeding | 8 | 2021 | 1363 | 0.410 |
Why?
|
Genetic Variation | 9 | 2022 | 6611 | 0.400 |
Why?
|
Nevirapine | 8 | 2024 | 273 | 0.390 |
Why?
|
Prevalence | 24 | 2024 | 15869 | 0.370 |
Why?
|
Hepatitis B Antibodies | 5 | 2023 | 156 | 0.370 |
Why?
|
Adult | 91 | 2024 | 223646 | 0.370 |
Why?
|
HIV Integrase Inhibitors | 3 | 2024 | 165 | 0.350 |
Why?
|
Humans | 158 | 2024 | 768166 | 0.340 |
Why?
|
Proviruses | 5 | 2023 | 320 | 0.340 |
Why?
|
Norovirus | 2 | 2021 | 37 | 0.340 |
Why?
|
Female | 107 | 2024 | 397192 | 0.320 |
Why?
|
Molecular Typing | 3 | 2019 | 115 | 0.320 |
Why?
|
Hepatitis B, Chronic | 2 | 2023 | 413 | 0.320 |
Why?
|
Diagnostic Errors | 1 | 2016 | 1281 | 0.320 |
Why?
|
Piperazines | 7 | 2024 | 2554 | 0.310 |
Why?
|
Circumcision, Male | 2 | 2020 | 148 | 0.300 |
Why?
|
Pregnancy | 36 | 2024 | 30256 | 0.300 |
Why?
|
Leukocytes, Mononuclear | 6 | 2023 | 1854 | 0.300 |
Why?
|
Cross-Sectional Studies | 21 | 2023 | 26379 | 0.290 |
Why?
|
Tuberculosis | 4 | 2023 | 2029 | 0.280 |
Why?
|
Infant, Newborn | 24 | 2024 | 26422 | 0.270 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 3 | 2023 | 381 | 0.270 |
Why?
|
Benzoxazines | 6 | 2024 | 320 | 0.270 |
Why?
|
Young Adult | 35 | 2024 | 60066 | 0.260 |
Why?
|
Infant Formula | 3 | 2018 | 194 | 0.250 |
Why?
|
Infant Mortality | 4 | 2019 | 752 | 0.250 |
Why?
|
Incidence | 15 | 2024 | 21538 | 0.240 |
Why?
|
Mutation, Missense | 4 | 2018 | 2592 | 0.240 |
Why?
|
Maternal Mortality | 2 | 2024 | 310 | 0.230 |
Why?
|
Alkynes | 5 | 2024 | 326 | 0.230 |
Why?
|
Receptors, CXCR4 | 3 | 2016 | 729 | 0.230 |
Why?
|
Male | 66 | 2024 | 364719 | 0.230 |
Why?
|
Drug Resistance, Multiple, Viral | 2 | 2018 | 52 | 0.220 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2019 | 4058 | 0.220 |
Why?
|
Cyclopropanes | 5 | 2024 | 436 | 0.220 |
Why?
|
Cytomegalovirus Infections | 3 | 2020 | 837 | 0.220 |
Why?
|
Infant | 24 | 2024 | 36535 | 0.210 |
Why?
|
Epidemics | 3 | 2022 | 517 | 0.210 |
Why?
|
AIDS-Related Opportunistic Infections | 3 | 2020 | 664 | 0.210 |
Why?
|
Middle Aged | 48 | 2024 | 223492 | 0.210 |
Why?
|
HIV Envelope Protein gp120 | 5 | 2016 | 925 | 0.200 |
Why?
|
Dideoxynucleosides | 2 | 2012 | 135 | 0.200 |
Why?
|
Rural Population | 5 | 2024 | 2325 | 0.200 |
Why?
|
Human papillomavirus 18 | 2 | 2019 | 125 | 0.190 |
Why?
|
Receptors, HIV | 2 | 2016 | 159 | 0.190 |
Why?
|
Public Policy | 2 | 2016 | 552 | 0.190 |
Why?
|
Papillomaviridae | 2 | 2024 | 1140 | 0.180 |
Why?
|
Latent Tuberculosis | 1 | 2023 | 224 | 0.180 |
Why?
|
Sapovirus | 1 | 2020 | 4 | 0.180 |
Why?
|
Immunoenzyme Techniques | 3 | 2013 | 1703 | 0.180 |
Why?
|
Human papillomavirus 16 | 2 | 2019 | 268 | 0.170 |
Why?
|
Condoms | 3 | 2022 | 337 | 0.170 |
Why?
|
Gastroenteritis | 2 | 2020 | 235 | 0.170 |
Why?
|
Adolescent | 22 | 2024 | 89169 | 0.170 |
Why?
|
Mass Screening | 5 | 2020 | 5458 | 0.170 |
Why?
|
Tetanus Toxoid | 1 | 2020 | 188 | 0.170 |
Why?
|
Insulin Resistance | 2 | 2024 | 3986 | 0.170 |
Why?
|
Disease Reservoirs | 1 | 2019 | 123 | 0.160 |
Why?
|
Africa | 4 | 2022 | 725 | 0.160 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 2 | 2018 | 283 | 0.160 |
Why?
|
Hepatitis B Vaccines | 1 | 2020 | 178 | 0.160 |
Why?
|
Adenine | 2 | 2023 | 995 | 0.160 |
Why?
|
Certification | 1 | 2022 | 420 | 0.160 |
Why?
|
Nucleosides | 1 | 2019 | 130 | 0.160 |
Why?
|
HIV Integrase | 1 | 2019 | 122 | 0.150 |
Why?
|
Immune Evasion | 1 | 2022 | 375 | 0.150 |
Why?
|
Dogs | 1 | 2023 | 3845 | 0.150 |
Why?
|
Syphilis | 2 | 2019 | 243 | 0.150 |
Why?
|
Virus Replication | 4 | 2021 | 2458 | 0.150 |
Why?
|
Milk, Human | 2 | 2012 | 490 | 0.150 |
Why?
|
Educational Status | 2 | 2016 | 2515 | 0.150 |
Why?
|
Paraffin Embedding | 1 | 2019 | 307 | 0.150 |
Why?
|
Tissue Fixation | 1 | 2019 | 246 | 0.150 |
Why?
|
Pregnancy Outcome | 7 | 2024 | 2972 | 0.150 |
Why?
|
Virus Activation | 1 | 2019 | 324 | 0.140 |
Why?
|
Premature Birth | 3 | 2022 | 1829 | 0.140 |
Why?
|
Enzyme Assays | 1 | 2017 | 103 | 0.140 |
Why?
|
Schools | 2 | 2016 | 1498 | 0.130 |
Why?
|
Viral Vaccines | 1 | 2022 | 596 | 0.130 |
Why?
|
Pyridazines | 1 | 2018 | 203 | 0.130 |
Why?
|
Blood Donors | 1 | 2018 | 343 | 0.130 |
Why?
|
Cluster Analysis | 4 | 2018 | 2732 | 0.130 |
Why?
|
Genes, env | 2 | 2013 | 96 | 0.130 |
Why?
|
Penile Neoplasms | 1 | 2017 | 158 | 0.130 |
Why?
|
Stillbirth | 3 | 2024 | 381 | 0.130 |
Why?
|
Students | 2 | 2016 | 1744 | 0.120 |
Why?
|
Sequence Analysis, DNA | 7 | 2015 | 4786 | 0.120 |
Why?
|
Longitudinal Studies | 9 | 2020 | 14783 | 0.120 |
Why?
|
Vulvar Neoplasms | 1 | 2017 | 266 | 0.120 |
Why?
|
Pregnancy, Unplanned | 1 | 2016 | 85 | 0.120 |
Why?
|
Evolution, Molecular | 4 | 2013 | 1896 | 0.120 |
Why?
|
HLA Antigens | 1 | 2020 | 1334 | 0.120 |
Why?
|
Asymptomatic Infections | 1 | 2015 | 136 | 0.120 |
Why?
|
Vascular Diseases | 1 | 2023 | 1162 | 0.120 |
Why?
|
Chemoprevention | 1 | 2017 | 327 | 0.120 |
Why?
|
Child Mortality | 1 | 2016 | 204 | 0.110 |
Why?
|
Contraception Behavior | 1 | 2016 | 186 | 0.110 |
Why?
|
Gene Frequency | 2 | 2019 | 3623 | 0.110 |
Why?
|
Cervix Uteri | 3 | 2024 | 577 | 0.110 |
Why?
|
Anus Neoplasms | 1 | 2017 | 336 | 0.110 |
Why?
|
Pandemics | 3 | 2022 | 8748 | 0.110 |
Why?
|
Sexual Partners | 2 | 2018 | 805 | 0.110 |
Why?
|
Sampling Studies | 1 | 2014 | 615 | 0.110 |
Why?
|
Hepatitis B e Antigens | 2 | 2023 | 135 | 0.110 |
Why?
|
South Africa | 3 | 2024 | 1873 | 0.110 |
Why?
|
Immunologic Memory | 1 | 2020 | 1377 | 0.110 |
Why?
|
Amino Acid Substitution | 2 | 2020 | 1743 | 0.100 |
Why?
|
Treatment Failure | 4 | 2024 | 2661 | 0.100 |
Why?
|
Cassia | 1 | 2012 | 3 | 0.100 |
Why?
|
Time Factors | 12 | 2021 | 40218 | 0.100 |
Why?
|
Hepacivirus | 1 | 2019 | 1344 | 0.100 |
Why?
|
Mastitis | 1 | 2012 | 42 | 0.100 |
Why?
|
Early Diagnosis | 1 | 2017 | 1194 | 0.100 |
Why?
|
Host-Pathogen Interactions | 3 | 2016 | 1469 | 0.100 |
Why?
|
Plasma | 1 | 2015 | 585 | 0.100 |
Why?
|
Leukocytes | 1 | 2020 | 2035 | 0.100 |
Why?
|
Didanosine | 2 | 2009 | 151 | 0.100 |
Why?
|
Prenatal Exposure Delayed Effects | 3 | 2024 | 2538 | 0.100 |
Why?
|
Diagnostic Tests, Routine | 3 | 2024 | 789 | 0.100 |
Why?
|
Cell Adhesion Molecules | 1 | 2018 | 1613 | 0.100 |
Why?
|
Specimen Handling | 1 | 2016 | 708 | 0.100 |
Why?
|
Immunity, Humoral | 1 | 2016 | 610 | 0.100 |
Why?
|
Disease Progression | 3 | 2019 | 13671 | 0.100 |
Why?
|
Hemoglobins | 1 | 2018 | 1531 | 0.100 |
Why?
|
Inflammation Mediators | 2 | 2018 | 1892 | 0.100 |
Why?
|
Bayes Theorem | 2 | 2017 | 2359 | 0.090 |
Why?
|
Attitude to Health | 1 | 2020 | 2025 | 0.090 |
Why?
|
Homosexuality, Male | 2 | 2022 | 1344 | 0.090 |
Why?
|
Geography | 1 | 2013 | 652 | 0.090 |
Why?
|
Receptors, Cell Surface | 2 | 2018 | 2819 | 0.090 |
Why?
|
Immunity, Innate | 2 | 2022 | 3080 | 0.090 |
Why?
|
Disease Transmission, Infectious | 1 | 2017 | 560 | 0.090 |
Why?
|
Carotid Artery Diseases | 1 | 2017 | 879 | 0.090 |
Why?
|
Hepatitis C | 2 | 2019 | 1595 | 0.090 |
Why?
|
Feasibility Studies | 1 | 2021 | 5315 | 0.090 |
Why?
|
Early Detection of Cancer | 2 | 2023 | 3239 | 0.090 |
Why?
|
Drug Resistance, Bacterial | 1 | 2017 | 1063 | 0.090 |
Why?
|
Antigens, CD | 2 | 2018 | 4035 | 0.090 |
Why?
|
Interleukin-6 | 3 | 2018 | 3228 | 0.080 |
Why?
|
Viral Tropism | 2 | 2023 | 102 | 0.080 |
Why?
|
Prospective Studies | 9 | 2024 | 54926 | 0.080 |
Why?
|
RNA | 3 | 2023 | 2720 | 0.080 |
Why?
|
Cytokines | 2 | 2015 | 7453 | 0.080 |
Why?
|
Genomics | 2 | 2022 | 5926 | 0.080 |
Why?
|
Antibodies, Neutralizing | 3 | 2023 | 2011 | 0.080 |
Why?
|
Cohort Studies | 13 | 2021 | 41754 | 0.080 |
Why?
|
Pregnancy Complications | 1 | 2022 | 2973 | 0.080 |
Why?
|
Retrospective Studies | 14 | 2023 | 81762 | 0.080 |
Why?
|
E-Selectin | 2 | 2023 | 577 | 0.080 |
Why?
|
Immunoglobulin M | 2 | 2023 | 1528 | 0.080 |
Why?
|
Molecular Sequence Data | 8 | 2014 | 17622 | 0.080 |
Why?
|
Point-of-Care Systems | 1 | 2017 | 1238 | 0.080 |
Why?
|
Sexually Transmitted Diseases | 1 | 2014 | 668 | 0.080 |
Why?
|
Hospitals, District | 1 | 2009 | 114 | 0.080 |
Why?
|
Plant Extracts | 1 | 2012 | 497 | 0.080 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 2 | 2023 | 693 | 0.080 |
Why?
|
Mycobacterium tuberculosis | 1 | 2019 | 1930 | 0.070 |
Why?
|
Sexual Behavior | 2 | 2016 | 2197 | 0.070 |
Why?
|
Sensitivity and Specificity | 3 | 2020 | 14729 | 0.070 |
Why?
|
Prenatal Diagnosis | 1 | 2015 | 1275 | 0.070 |
Why?
|
Thymidine | 1 | 2007 | 297 | 0.070 |
Why?
|
Counseling | 1 | 2015 | 1554 | 0.070 |
Why?
|
Intercellular Adhesion Molecule-1 | 2 | 2023 | 1134 | 0.070 |
Why?
|
Biopsy | 1 | 2019 | 6793 | 0.070 |
Why?
|
RNA-Directed DNA Polymerase | 1 | 2007 | 223 | 0.070 |
Why?
|
Acidosis, Lactic | 1 | 2007 | 145 | 0.070 |
Why?
|
Endothelium, Vascular | 1 | 2018 | 4427 | 0.060 |
Why?
|
Epitopes | 2 | 2023 | 2528 | 0.060 |
Why?
|
Nitriles | 2 | 2023 | 980 | 0.060 |
Why?
|
Triage | 2 | 2023 | 997 | 0.060 |
Why?
|
Antiviral Agents | 3 | 2024 | 3073 | 0.060 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2023 | 4415 | 0.060 |
Why?
|
Child, Preschool | 7 | 2024 | 42669 | 0.060 |
Why?
|
Vitamin D Deficiency | 1 | 2014 | 1388 | 0.060 |
Why?
|
Immunocompromised Host | 2 | 2020 | 863 | 0.060 |
Why?
|
Amino Acid Sequence | 4 | 2020 | 13421 | 0.060 |
Why?
|
Hospitalization | 3 | 2020 | 10840 | 0.060 |
Why?
|
Acetic Acid | 1 | 2023 | 59 | 0.060 |
Why?
|
Risk Factors | 10 | 2024 | 74944 | 0.060 |
Why?
|
Base Sequence | 4 | 2019 | 12421 | 0.050 |
Why?
|
Child | 8 | 2023 | 80917 | 0.050 |
Why?
|
Pre-Eclampsia | 1 | 2013 | 1255 | 0.050 |
Why?
|
Hepatitis B Core Antigens | 1 | 2023 | 90 | 0.050 |
Why?
|
Tropism | 1 | 2023 | 44 | 0.050 |
Why?
|
Parturition | 2 | 2019 | 455 | 0.050 |
Why?
|
Molecular Epidemiology | 2 | 2015 | 473 | 0.050 |
Why?
|
Colposcopy | 1 | 2023 | 151 | 0.050 |
Why?
|
Epitopes, T-Lymphocyte | 2 | 2020 | 827 | 0.050 |
Why?
|
Computational Biology | 1 | 2015 | 3568 | 0.050 |
Why?
|
Africa South of the Sahara | 2 | 2021 | 752 | 0.050 |
Why?
|
Prognosis | 3 | 2019 | 30010 | 0.050 |
Why?
|
Withholding Treatment | 2 | 2019 | 620 | 0.050 |
Why?
|
Genome, Viral | 2 | 2020 | 674 | 0.050 |
Why?
|
Killer Cells, Natural | 2 | 2022 | 2211 | 0.050 |
Why?
|
Vaginal Smears | 1 | 2024 | 505 | 0.050 |
Why?
|
Anemia | 1 | 2011 | 1514 | 0.050 |
Why?
|
Drug Therapy, Combination | 3 | 2021 | 6316 | 0.050 |
Why?
|
Case-Control Studies | 5 | 2018 | 22291 | 0.050 |
Why?
|
Feces | 2 | 2018 | 1511 | 0.050 |
Why?
|
Treatment Outcome | 6 | 2018 | 65371 | 0.050 |
Why?
|
Genes, pol | 1 | 2020 | 53 | 0.050 |
Why?
|
Rh-Hr Blood-Group System | 1 | 2021 | 64 | 0.050 |
Why?
|
Vitamin D | 1 | 2014 | 3311 | 0.040 |
Why?
|
Databases, Nucleic Acid | 1 | 2021 | 204 | 0.040 |
Why?
|
Pilot Projects | 3 | 2021 | 8741 | 0.040 |
Why?
|
Polymerase Chain Reaction | 2 | 2020 | 6082 | 0.040 |
Why?
|
Algorithms | 3 | 2020 | 14164 | 0.040 |
Why?
|
Proportional Hazards Models | 3 | 2019 | 12543 | 0.040 |
Why?
|
Polymorphism, Genetic | 1 | 2010 | 4249 | 0.040 |
Why?
|
Genes, MHC Class II | 1 | 2020 | 433 | 0.040 |
Why?
|
Kenya | 1 | 2022 | 757 | 0.040 |
Why?
|
Monocytes | 2 | 2019 | 2605 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2017 | 7477 | 0.040 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2007 | 2204 | 0.040 |
Why?
|
AIDS Serodiagnosis | 1 | 2020 | 220 | 0.040 |
Why?
|
Vaccination | 2 | 2023 | 3437 | 0.040 |
Why?
|
Pyrimidines | 2 | 2023 | 3048 | 0.040 |
Why?
|
Interferon-gamma | 2 | 2020 | 3160 | 0.040 |
Why?
|
pol Gene Products, Human Immunodeficiency Virus | 1 | 2018 | 41 | 0.040 |
Why?
|
Laboratories | 1 | 2022 | 463 | 0.040 |
Why?
|
Transcription, Genetic | 1 | 2012 | 7608 | 0.040 |
Why?
|
Alanine | 1 | 2021 | 614 | 0.040 |
Why?
|
Microbial Sensitivity Tests | 2 | 2018 | 1967 | 0.040 |
Why?
|
Virus Internalization | 2 | 2012 | 504 | 0.040 |
Why?
|
Animals | 5 | 2023 | 169246 | 0.040 |
Why?
|
Postpartum Period | 2 | 2016 | 1198 | 0.040 |
Why?
|
Ribavirin | 1 | 2019 | 395 | 0.040 |
Why?
|
Chromosomes, Human | 1 | 2019 | 438 | 0.040 |
Why?
|
Aged | 4 | 2024 | 171504 | 0.040 |
Why?
|
Telemedicine | 1 | 2015 | 3109 | 0.040 |
Why?
|
Sequence Analysis, RNA | 2 | 2018 | 2040 | 0.040 |
Why?
|
Likelihood Functions | 1 | 2020 | 994 | 0.040 |
Why?
|
Health Services Accessibility | 1 | 2015 | 5520 | 0.030 |
Why?
|
Recombination, Genetic | 1 | 2022 | 1525 | 0.030 |
Why?
|
BCG Vaccine | 1 | 2020 | 381 | 0.030 |
Why?
|
Clinical Laboratory Techniques | 1 | 2022 | 747 | 0.030 |
Why?
|
Drug Resistance | 1 | 2022 | 1599 | 0.030 |
Why?
|
Amino Acids | 1 | 2022 | 1716 | 0.030 |
Why?
|
Sequence Alignment | 1 | 2020 | 2179 | 0.030 |
Why?
|
Neonatal Screening | 1 | 2020 | 620 | 0.030 |
Why?
|
United Nations | 1 | 2016 | 151 | 0.030 |
Why?
|
Interferon-alpha | 1 | 2019 | 910 | 0.030 |
Why?
|
Escherichia coli | 2 | 2017 | 4214 | 0.030 |
Why?
|
Least-Squares Analysis | 1 | 2015 | 367 | 0.030 |
Why?
|
Birth Weight | 1 | 2023 | 2121 | 0.030 |
Why?
|
Neutralization Tests | 1 | 2016 | 739 | 0.030 |
Why?
|
Population Density | 1 | 2014 | 193 | 0.030 |
Why?
|
Phlebotomy | 1 | 2015 | 138 | 0.030 |
Why?
|
Drug Resistance, Microbial | 1 | 2017 | 830 | 0.030 |
Why?
|
Drug Combinations | 1 | 2020 | 2089 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2020 | 1793 | 0.030 |
Why?
|
Infant, Low Birth Weight | 1 | 2018 | 871 | 0.030 |
Why?
|
Placenta | 1 | 2023 | 1725 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12077 | 0.030 |
Why?
|
Congenital Abnormalities | 1 | 2018 | 703 | 0.030 |
Why?
|
Awareness | 1 | 2018 | 654 | 0.030 |
Why?
|
Follow-Up Studies | 3 | 2021 | 39348 | 0.030 |
Why?
|
Contraceptives, Oral | 1 | 2016 | 560 | 0.030 |
Why?
|
Double-Blind Method | 2 | 2017 | 12465 | 0.030 |
Why?
|
Interleukin-2 | 1 | 2020 | 1895 | 0.030 |
Why?
|
Papillomavirus Vaccines | 1 | 2019 | 497 | 0.030 |
Why?
|
Intention | 1 | 2016 | 347 | 0.030 |
Why?
|
Peripartum Period | 1 | 2014 | 137 | 0.030 |
Why?
|
Ultrasonography, Prenatal | 1 | 2021 | 1772 | 0.030 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2015 | 340 | 0.030 |
Why?
|
T-Lymphocytes | 2 | 2020 | 10266 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 2017 | 640 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2018 | 15662 | 0.020 |
Why?
|
Cytopathogenic Effect, Viral | 1 | 2012 | 152 | 0.020 |
Why?
|
Cost-Benefit Analysis | 2 | 2015 | 5536 | 0.020 |
Why?
|
Pregnancy Proteins | 1 | 2013 | 222 | 0.020 |
Why?
|
Virus Attachment | 1 | 2012 | 56 | 0.020 |
Why?
|
Medicine, African Traditional | 1 | 2012 | 31 | 0.020 |
Why?
|
Gestational Age | 1 | 2021 | 3621 | 0.020 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2014 | 425 | 0.020 |
Why?
|
Delivery, Obstetric | 1 | 2019 | 954 | 0.020 |
Why?
|
HIV Core Protein p24 | 1 | 2012 | 247 | 0.020 |
Why?
|
Neutropenia | 1 | 2017 | 892 | 0.020 |
Why?
|
Models, Molecular | 1 | 2022 | 5403 | 0.020 |
Why?
|
Plant Roots | 1 | 2012 | 122 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2023 | 3216 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2018 | 4055 | 0.020 |
Why?
|
Plants, Medicinal | 1 | 2012 | 167 | 0.020 |
Why?
|
Codon | 1 | 2013 | 599 | 0.020 |
Why?
|
Placebos | 1 | 2015 | 1667 | 0.020 |
Why?
|
Continuity of Patient Care | 1 | 2018 | 1078 | 0.020 |
Why?
|
Community Health Services | 1 | 2016 | 659 | 0.020 |
Why?
|
Family Characteristics | 1 | 2016 | 1003 | 0.020 |
Why?
|
Goals | 1 | 2016 | 717 | 0.020 |
Why?
|
Herpes Genitalis | 1 | 2011 | 149 | 0.020 |
Why?
|
Antirheumatic Agents | 1 | 2020 | 1381 | 0.020 |
Why?
|
Lactation | 1 | 2012 | 392 | 0.020 |
Why?
|
Receptors, CCR5 | 1 | 2012 | 491 | 0.020 |
Why?
|
Herpesvirus 2, Human | 1 | 2011 | 191 | 0.020 |
Why?
|
Sex Distribution | 1 | 2015 | 2278 | 0.020 |
Why?
|
Suppression, Genetic | 1 | 2010 | 190 | 0.020 |
Why?
|
Phytotherapy | 1 | 2012 | 298 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 560 | 0.020 |
Why?
|
Mothers | 1 | 2020 | 2209 | 0.020 |
Why?
|
Infant Nutritional Physiological Phenomena | 1 | 2012 | 352 | 0.020 |
Why?
|
Cost of Illness | 1 | 2019 | 1951 | 0.020 |
Why?
|
Tanzania | 1 | 2014 | 1407 | 0.020 |
Why?
|
Alleles | 1 | 2020 | 6894 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 3671 | 0.020 |
Why?
|
HLA-B Antigens | 1 | 2010 | 330 | 0.020 |
Why?
|
Ambulatory Care Facilities | 1 | 2015 | 939 | 0.020 |
Why?
|
Risk-Taking | 1 | 2014 | 1023 | 0.020 |
Why?
|
Survival Analysis | 2 | 2013 | 10101 | 0.020 |
Why?
|
Seasons | 1 | 2014 | 1524 | 0.020 |
Why?
|
Perinatal Care | 1 | 2011 | 245 | 0.020 |
Why?
|
Sequence Homology | 1 | 2008 | 197 | 0.020 |
Why?
|
Interleukin-10 | 1 | 2014 | 1183 | 0.020 |
Why?
|
Capsid Proteins | 1 | 2011 | 468 | 0.020 |
Why?
|
Gene Expression | 1 | 2021 | 7598 | 0.020 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2012 | 2748 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2022 | 16045 | 0.020 |
Why?
|
Population Surveillance | 1 | 2018 | 2596 | 0.020 |
Why?
|
Protease Inhibitors | 1 | 2011 | 751 | 0.020 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2009 | 238 | 0.020 |
Why?
|
Africa, Southern | 1 | 2007 | 60 | 0.020 |
Why?
|
Laboratories, Hospital | 1 | 2009 | 192 | 0.020 |
Why?
|
Drug Tolerance | 1 | 2009 | 365 | 0.020 |
Why?
|
Genetic Heterogeneity | 1 | 2011 | 736 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2013 | 2862 | 0.020 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2019 | 2333 | 0.020 |
Why?
|
Lactates | 1 | 2007 | 401 | 0.020 |
Why?
|
Family Planning Services | 1 | 2010 | 279 | 0.020 |
Why?
|
Computer Simulation | 1 | 2020 | 6283 | 0.020 |
Why?
|
Health Personnel | 1 | 2020 | 3385 | 0.020 |
Why?
|
Risk | 1 | 2018 | 9613 | 0.020 |
Why?
|
Motivation | 1 | 2016 | 2020 | 0.020 |
Why?
|
Developmental Disabilities | 1 | 2014 | 1518 | 0.020 |
Why?
|
Selection, Genetic | 1 | 2010 | 877 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7852 | 0.020 |
Why?
|
Demography | 1 | 2010 | 1641 | 0.020 |
Why?
|
Linear Models | 1 | 2015 | 5884 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2015 | 2118 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2013 | 4860 | 0.020 |
Why?
|
Point Mutation | 1 | 2010 | 1596 | 0.010 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2011 | 1801 | 0.010 |
Why?
|
Research Design | 1 | 2020 | 6211 | 0.010 |
Why?
|
Protein Binding | 1 | 2016 | 9343 | 0.010 |
Why?
|
Liver Neoplasms | 1 | 2019 | 4362 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 3814 | 0.010 |
Why?
|
Immunologic Factors | 1 | 2012 | 1596 | 0.010 |
Why?
|
Child Development | 1 | 2014 | 2330 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2014 | 4352 | 0.010 |
Why?
|
Politics | 1 | 2009 | 822 | 0.010 |
Why?
|
Phenotype | 1 | 2019 | 16726 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2018 | 10399 | 0.010 |
Why?
|
Sex Factors | 1 | 2014 | 10632 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2012 | 5151 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2012 | 10760 | 0.010 |
Why?
|
Acute Disease | 1 | 2009 | 7243 | 0.010 |
Why?
|
Patient Compliance | 1 | 2009 | 2697 | 0.010 |
Why?
|
Age Factors | 1 | 2015 | 18412 | 0.010 |
Why?
|
Logistic Models | 1 | 2013 | 13290 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2012 | 19015 | 0.010 |
Why?
|
Patient Selection | 1 | 2007 | 4260 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2011 | 15948 | 0.010 |
Why?
|
Cell Line | 1 | 2006 | 15597 | 0.010 |
Why?
|